Alexis Light1, Lin-Fan Wang2, Alexander Zeymo3, Veronica Gomez-Lobo4. 1. Department of Women's and Infants' Services, MedStar Washington Hospital Center, 110 Irving St NW, Washington, DC 20010, USA. Electronic address: Alexis.D.Light@gmail.com. 2. Mazzoni Center, 1438 Bainbridge St, Philadelphia, PA 19147, USA. 3. Department of Biostatistics and Biomedical Informatics, MedStar Health Research Institute, 6525 Belcrest Rd #700, Hyattsville, MD 20782, USA. 4. Department of Women's and Infants' Services, MedStar Washington Hospital Center, 110 Irving St NW, Washington, DC 20010, USA; Director of Pediatric and Adolescent Gynecology, Children's National Health System and MedStar Washington Hospital Center, 110 Irving St NW, Washington, DC 20010, USA.
Abstract
OBJECTIVES: Female-to-male (FTM) transgender men (affirmed males) can experience planned and unplanned pregnancy during and after testosterone therapy. We conducted an exploratory study to understand current contraceptive practices and fertility desires among transgender men during and after transitioning. STUDY DESIGN: Self-identified transgender and transmasculine individuals assigned female at birth, ages 18-45, completed an anonymous online survey derived from standardized family planning surveys. We recruited participants from LGBT health centers, online listservs, and online groups for transgender men and used a mixed-methods analysis to evaluate quantitative and qualitative data. RESULTS: Of the one hundred and ninety-seven participants included in the study, the median age was 30 years old, most respondents were white, and 86% were taking masculinizing hormones (testosterone). Of the 60 pregnancies reported, 10 (17%) pregnancies occurred after stopping testosterone, 1 (1.6%) while taking testosterone irregularly, and 5 of 7 abortions occurred in participants who had been using testosterone in the past. Over half of the respondents desired at least one child, and a quarter reported fears of not getting pregnant. The majority of participants reporting using contraception (n=110, 60.1%), with condoms and pills used most commonly (n=90, 49.2% and n=62, 33.9% respectively). Methods of contraception used did not differ between testosterone users and non-users, except for hormonal IUDs (20% testosterone versus 7% non-testosterone). Thirty participants (16.4%) believed that testosterone was a form of contraception, and 10 (5.5%) participants reported that their healthcare providers advised testosterone as contraception. CONCLUSION: Transgender men use contraception and can experience pregnancy and abortion, even after transitioning socially and hormonally. Transgender men need counseling and care regarding reproductive health, including contraceptive and conception counseling. IMPLICATIONS: Providers should be aware that transgender men may desire pregnancy and use contraception; this study highlights the need for further research regarding fertility, fertility desires, and optimal contraception among transgender men.
OBJECTIVES: Female-to-male (FTM) transgender men (affirmed males) can experience planned and unplanned pregnancy during and after testosterone therapy. We conducted an exploratory study to understand current contraceptive practices and fertility desires among transgender men during and after transitioning. STUDY DESIGN: Self-identified transgender and transmasculine individuals assigned female at birth, ages 18-45, completed an anonymous online survey derived from standardized family planning surveys. We recruited participants from LGBT health centers, online listservs, and online groups for transgender men and used a mixed-methods analysis to evaluate quantitative and qualitative data. RESULTS: Of the one hundred and ninety-seven participants included in the study, the median age was 30 years old, most respondents were white, and 86% were taking masculinizing hormones (testosterone). Of the 60 pregnancies reported, 10 (17%) pregnancies occurred after stopping testosterone, 1 (1.6%) while taking testosterone irregularly, and 5 of 7 abortions occurred in participants who had been using testosterone in the past. Over half of the respondents desired at least one child, and a quarter reported fears of not getting pregnant. The majority of participants reporting using contraception (n=110, 60.1%), with condoms and pills used most commonly (n=90, 49.2% and n=62, 33.9% respectively). Methods of contraception used did not differ between testosterone users and non-users, except for hormonal IUDs (20% testosterone versus 7% non-testosterone). Thirty participants (16.4%) believed that testosterone was a form of contraception, and 10 (5.5%) participants reported that their healthcare providers advised testosterone as contraception. CONCLUSION: Transgender men use contraception and can experience pregnancy and abortion, even after transitioning socially and hormonally. Transgender men need counseling and care regarding reproductive health, including contraceptive and conception counseling. IMPLICATIONS: Providers should be aware that transgender men may desire pregnancy and use contraception; this study highlights the need for further research regarding fertility, fertility desires, and optimal contraception among transgender men.
Authors: Brett Stark; Jaclyn M W Hughto; Brittany M Charlton; Madeline B Deutsch; Jennifer Potter; Sari L Reisner Journal: Contraception Date: 2019-08-07 Impact factor: 3.375
Authors: Diane Chen; Moira A Kyweluk; Afiya Sajwani; Elisa J Gordon; Emilie K Johnson; Courtney A Finlayson; Teresa K Woodruff Journal: LGBT Health Date: 2019-04 Impact factor: 4.151
Authors: Cory Kosche; Matthew Mansh; Mark Luskus; Andy Nguyen; Gabriel Martinez-Diaz; David Inwards-Breland; Howa Yeung; Markus D Boos Journal: Pediatr Dermatol Date: 2019-07-01 Impact factor: 1.588
Authors: Rebecca L Taub; Simon Adriane Ellis; Genevieve Neal-Perry; Amalia S Magaret; Sarah W Prager; Elizabeth A Micks Journal: Am J Obstet Gynecol Date: 2020-02-08 Impact factor: 8.661